We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Files Patent Infringement Suit Against Premaitha
News

Illumina Files Patent Infringement Suit Against Premaitha

Illumina Files Patent Infringement Suit Against Premaitha
News

Illumina Files Patent Infringement Suit Against Premaitha

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina Files Patent Infringement Suit Against Premaitha "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. and its wholly-owned subsidiary, Verinata Health Inc., (together "Illumina") have filed a patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. 

The patents asserted are European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom, Inc. and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent (UK) 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT). The suit accuses Premaitha's IONA® Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood. 

"Illumina filed this suit to actively defend its intellectual property rights. We will also continue to monitor the NIPT field and file patent suits where appropriate when our patents are infringed," said Charles Dadswell, Senior Vice President and General Counsel for Illumina.

Advertisement